These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3864428)

  • 41. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
    Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
    Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine.
    Kishimoto W; Hiroi T; Sakai K; Funae Y; Igarashi T
    Res Commun Mol Pathol Pharmacol; 1997 Dec; 98(3):273-92. PubMed ID: 9485522
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin.
    Steiner E; Alván G; Garle M; Maguire JH; Lind M; Nilson SO; Tomson T; McClanahan JS; Sjöqvist F
    Clin Pharmacol Ther; 1987 Sep; 42(3):326-33. PubMed ID: 3621788
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
    Ha HR; Chen J; Freiburghaus AU; Follath F
    Br J Clin Pharmacol; 1995 Mar; 39(3):321-6. PubMed ID: 7619675
    [TBL] [Abstract][Full Text] [Related]  

  • 45. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.
    Mellström B; Bertilsson L; Säwe J; Schulz HU; Sjöqvist F
    Clin Pharmacol Ther; 1981 Aug; 30(2):189-93. PubMed ID: 7249504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS; Tucker GT; Woods HF
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
    Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
    Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results.
    Vincent-Viry M; Deshayes S; Mothe O; Siest G; Galteau MM
    J Pharm Pharmacol; 1988 Oct; 40(10):695-700. PubMed ID: 2907535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.
    Zanger UM; Vilbois F; Hardwick JP; Meyer UA
    Biochemistry; 1988 Jul; 27(15):5447-54. PubMed ID: 3052575
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
    Ebner T; Eichelbaum M
    Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lack of defect in oxidative hydroxylation of debrisoquine in a patient with halothane hepatitis.
    Toutoungi M; Magnenat D
    Eur J Clin Pharmacol; 1990; 38(6):633-4. PubMed ID: 2373140
    [No Abstract]   [Full Text] [Related]  

  • 52. Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects.
    Woolhouse NM; Adjepon-Yamoah KK; Mellström B; Hedman A; Bertilsson L; Sjöqvist F
    Clin Pharmacol Ther; 1984 Sep; 36(3):374-8. PubMed ID: 6467797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation.
    Irshaid YM; al-Hadidi HF; Latif A; Awwadi F; al-Zoubi M; Rawashdeh NM
    Eur J Drug Metab Pharmacokinet; 1996; 21(4):301-7. PubMed ID: 9074894
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytochrome-P450-dependent hydroxylation in cluster headache.
    Tomson T; Waldenlind E; Ekbom K
    Cephalalgia; 1992 Jun; 12(3):161-4. PubMed ID: 1623511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of inflammation on the rabbit hepatic cytochrome P-450 isoenzymes: alterations in the kinetics and dynamics of tolbutamide.
    Parent C; Bélanger PM; Jutras L; du Souich P
    J Pharmacol Exp Ther; 1992 May; 261(2):780-7. PubMed ID: 1578383
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cigarette smoking and theophylline clearance and metabolism.
    Grygiel JJ; Birkett DJ
    Clin Pharmacol Ther; 1981 Oct; 30(4):491-6. PubMed ID: 7285483
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deficient metabolism of debrisoquine and sparteine.
    Inaba T; Otton SV; Kalow W
    Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.
    Böttiger Y; Dostert P; Benedetti MS; Bani M; Fiorentini F; Casati M; Poggesti I; Alm C; Alvan G; Bertilsson L
    Br J Clin Pharmacol; 1996 Dec; 42(6):707-11. PubMed ID: 8971425
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects.
    Batty KT; Davis TM; Ilett KF; Dusci LJ; Langton SR
    Br J Clin Pharmacol; 1995 Mar; 39(3):305-11. PubMed ID: 7619673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.